2. Academic Validation
  3. Toppling the HAT to Treat Lethal Prostate Cancer

Toppling the HAT to Treat Lethal Prostate Cancer

  • Cancer Discov. 2021 May;11(5):1011-1013. doi: 10.1158/2159-8290.CD-21-0184.
Reyaz Ur Rasool 1,  Ramakrishnan Natesan 1,  Irfan A Asangani 2 3
Affiliations

Affiliations

  • 1 Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • 2 Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. asangani@upenn.edu.
  • 3 Department of Cancer Biology, Abramson Family Cancer Research Institute, Penn Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
PMID: 33947717 DOI: 10.1158/2159-8290.CD-21-0184
Abstract

In this issue of Cancer Discovery, Welti and colleagues demonstrate a positive correlation between the expression of the Histone Acetyltransferase paralogs CBP and p300 with increased Androgen Receptor (AR) signaling and androgen deprivation therapy resistance in advanced prostate Cancer. CCS1477, a selective inhibitor of p300/CBP bromodomain, disrupts AR- and MYC-regulated gene expression, suppresses tumor growth in vivo in multiple castration-resistant prostate Cancer xenograft models, and modulates biomarker expression in early clinical evaluation, providing a novel therapeutic approach for AR-addicted advanced prostate Cancer.See related article by Welti et al., p. 1118.

Figures
Products